Early Access — free while we kick the tires
EdgarHawk

Lehmkuhl Greg

Director

Director

Latest: Director buying · May 2026

2 filings analyzed · 1 company · Latest 2026-05-18

Companies

Company Buys Sells Direction
AGREE REALTY CORP ADC 4 0 Net buying

Activity

May 2026
2026-05-18 AGREE REALTY CORP ADC
medium
Buy
750 shares
$56,318
Significance 6/10

Director Greg Lehmkuhl bought 750 ADC shares at $75.09 on 2026-05-14, raising holdings to 34,464 shares

Lehmkuhl purchased 750 shares for $56,317.50 at $75.09 per share, increasing his stake by 2.2% to 34,464 shares. The purchase occurs with ADC trading at $75.55 (current), down 4.9% over 30 days and 4.6% over 90 days from higher levels, though still within the 52-week range of $69.56–$82.08. Across his open-market history, Lehmkuhl's 3 prior buys averaged +0.6% return over 30 days and +12.7% over 90 days with a 100% win rate, though his same-ticker ADC history shows mixed recent results: a 2025-09-05 buy posted -3.1% in 30 days and +2.1% in 90 days, while a 2024-05-23 buy posted +4.2% in 30 days and +23.3% in 90 days. ADC's fundamentals remain solid with $200.8M in latest-quarter revenue, $62.1M net income, 16.4% annual revenue growth, and a $9.1B market cap, though the P/E of 41.28 reflects elevated valuations relative to near-term returns.

September 2025
2025-09-08 AGREE REALTY CORP ADC
medium
Buy
750 shares
$54,630
Significance 5/10

Director Greg Lehmkuhl buys 750 ADC shares at $72.84; grows stake to 27,683 shares (+2.8%)

Director Greg Lehmkuhl purchased 750 shares of AGREE REALTY CORP at $72.84 on 2025-09-05, increasing his holdings from 26,933 to 27,683 shares. The current price of $72.62 is 8.2% below the 52-week high of $79.12, positioning this purchase near recent lows. Among Lehmkuhl's prior purchases at ADC, one of his two previous buys (in May 2024) showed strong subsequent performance with a 90-day return of +23.3%, while the other (December 2023) declined 9.7% over the same period—a mixed track record at this ticker. The company shows solid operational health with $175.5M in latest quarterly revenue, $49.2M net income, and 14.8% annual revenue growth, though the elevated P/E of 43.23 suggests the stock is priced for continued expansion. This open-market purchase represents continued accumulation in a moderately valued REIT, but the mixed historical timing outcomes at this specific ticker and modest position increase (+2.8%) indicate measured rather than aggressive conviction.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access